The SARS-CoV-2 spike glycoprotein is a focal point for vaccine immunogen and therapeutic antibody design, and also serves as a critical antigen in the evaluation of immune responses to COVID-19. A common feature amongst enveloped viruses such as SARS-CoV-2 and HIV-1 is the propensity for displaying host-derived glycans on entry spike proteins. Similarly displayed glycosylation motifs can serve as the basis for glyco-epitope mediated cross-reactivity by antibodies, which can have important implications on virus neutralization, antibody-dependent enhancement (ADE) of infection, and the interpretation of antibody titers in serological assays. From a panel of nine anti-HIV-1 gp120 reactive antibodies, we selected two (PGT126 and PGT128) that displayed high levels of cross-reactivity with the SARS-CoV-2 spike. We report that these antibodies are incapable of neutralizing pseudoviruses expressing SARS-CoV-2 spike proteins and are unlikely to mediate ADE via FcγRII receptor engagement. Nevertheless, ELISA and other immunoreactivity experiments demonstrate these antibodies are capable of binding the SARS-CoV-2 spike in a glycan-dependent manner. These results contribute to the growing literature surrounding SARS-CoV-2 S cross-reactivity, as we demonstrate the ability for cross-reactive antibodies to interfere in immunoassays.
【저자키워드】 Microbiology, Virology, 【초록키워드】 COVID-19, antibodies, SARS-CoV-2, immune response, glycosylation, antibody, Antibody-dependent enhancement, Infection, virus, ELISA, Antigen, cross-reactivity, immunoassays, pseudovirus, serological assays, SARS-CoV-2 spike glycoprotein, SARS-CoV-2 spike protein, therapeutic, HIV-1, Interpretation, Antibody titer, Virus neutralization, Neutralizing, experiment, ADE, Critical, glycan, binding, Spike proteins, cross-reactive antibody, immunoreactivity, SARS-CoV-2 S, motif, gp120, receptor engagement, implication, reactive, selected, nine, unlikely, contribute, interfere, expressing, displaying, the SARS-CoV-2, vaccine immunogen, 【제목키워드】 antibody, Spike protein, glycan, block viral entry, reactive, the SARS-CoV-2,